ReviewInternational journal of molecular sciences2021
Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Trends in pulmonary embolism mortality among older adults with lung cancer in the united States, 1999-2020.Journal of thrombosis and thrombolysis · 2026Article
- Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies.Molecular and cellular biochemistry · 2025Review
- Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: a propensity score-matched study.Future oncology (London, England) · 2025Article
- Lung cancer in non-smoking women (LCINSW): from risk factors to precision therapy.Cancer metastasis reviews · 2025Review
- GPER1 is involved in shaping tumor immune microenvironment and its expression is decreased in NSCLC tumorigenesis.Scientific reports · 2025Article
- Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer.World journal of gastroenterology · 2025Article
- Effect of Gender on Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Real-World Study.Biomedicines · 2025Article
- Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study.Frontiers in immunology · 2025Observational
- Decoding sex differences in human immunity through systems immunology.Oxford open immunology · 2025Review
- Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches.Frontiers in pharmacology · 2025Article
- Efficacy and influencing factors of immunotherapy crossover combined with targeted therapy in advanced esophageal cancer patients following first-line chemotherapy combined with immunotherapy failure.American journal of cancer research · 2025Article
- Comparing the utility of lung function parameters and fractional exhaled nitric oxide in predicting lung cancer.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2024Article
- CD147 TagSNP is associated with the vulnerability to lung cancer in the Chinese population: a case-control study.Discover oncology · 2024Article
- Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Lung cancer in females-sex-based differences from males in epidemiology, biology, and outcomes: a narrative review.Translational lung cancer research · 2024Review
- Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene-A Literature Review and Single-Center Experience.Biomedicines · 2024Review
- Long-term outcomes of lung cancer screening in males and females.Lung cancer (Amsterdam, Netherlands) · 2023Article
- Plasma D-dimer and interleukin-6 are associated with treatment response and progression-free survival in advanced NSCLC patients on anti-PD-1 therapy.Cancer medicine · 2023Review
- The Impact of Liquid Biopsies Positive forDiagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In developed countries, lung cancer is the leading cause of cancer-related death in both sexes. Although cigarette smoking represents the principal risk factor for lung cancer in females, the higher proportion of this neoplasm among non-smoking women as compared with non-smoking men implies distinctive biological aspects between the two sexes. Gender differences depend not only on genetic, environmental, and hormonal factors but also on the immune system, and all these aspects are closely interconnected. In the last few years, it has been confirmed that the immune system plays a fundamental role in cancer evolution and response to oncological treatments, specifically immunotherapy, with documented distinctions between men and women. Consequently, in order to correctly assess cancer responses and disease control, considering only age and reproductive status, the results of studies conducted in female patients would probably not categorically apply to male patients and vice versa. The aim of this article is to review recent data about gender disparities in both healthy subjects' immune system and lung cancer patients; furthermore, studies concerning gender differences in response to lung cancer immunotherapy are examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.